Dr Reddy's Lab said today that all the litigation claims against the company over Revlimid have been dismissed in the USA court.
In Nov 2022, Antitrust case filed against Dr Reddys Labs in the US over maintaining a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation with other pharmaceutical companies.
The complaint alleges that the challenged agreements improperly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026. The complaint seeks damages for purported overpayments and equitable relief.
Dr Reddy's Lab and Dr. Reddy’s Laboratories, Inc. (a wholly owned subsidiary of the Company) had been named as defendants, along with Celgene, Bristol Myers Squibb, and several other generic pharmaceutical companies, in a complaint that asserts claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States.
Generic drugmaker Dr Reddy's Labs reported a 12.2% rise in second-quarter profit which was gained by the launch of the generic version of Lenalidomide capsules in the U.S. market.
